Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.

Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.
Skin Therapy Lett. 2017 Sep;22(5):5-7
Authors: Monjazeb S, Wilson J
Abstract
Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy," which target pathways more specific to neoplastic proliferation than traditional chemotherapeutic agents. Adverse effects of such treatments are thought to be less severe, but can still be significant. Because EGFR is preferentially expressed in epithelial tissues, including the skin and hair follicle, cutaneous side effects of these agents are quite common. Not only can these toxicities severely affect patients' quality of life, but in some specific instances, they can be associated with increased response to therapy. It is of paramount importance that clinicians familiarize themselves with and understand the basic management of the range of cutaneous adverse effects caused by these drugs.
PMID: 28888217 [PubMed - in process]

Source: Skin Therapy Letter - September 1, 2017 Category: Dermatology Authors: Monjazeb S, Wilson J Tags: Skin Therapy Lett Source Type: research